U.S. Tech Hardware Stock News

Some investors may be wondering if Eli Lilly is still worth its current price, or if the recent run has already baked in too much optimism. The stock closed at US$878.24, with returns of a 3.5% decline over 7 days, a 16.5% decline over 30 days, an 18.7% decline year to date, a 7.1% gain over 1 year, a 156.0% gain over 3 years and a very large gain over 5 years. Recent headlines have focused on Eli Lilly's role in high profile drug categories, including weight management and other blockbuster...

Structure Therapeutics recently reported positive topline Phase 2 ACCESS II and related study data for aleniglipron, an oral once-daily GLP-1 receptor agonist for people living with obesity or overweight, showing clinically meaningful and statistically significant weight loss alongside a tolerability profile consistent with its drug class. A particularly interesting aspect is that aleniglipron’s weight loss efficacy was described as comparable to injectable GLP-1 therapies while using an...

With no single headline event driving attention, RLJ Lodging Trust (RLJ) is drawing interest as investors weigh its recent share performance in relation to its hotel focused REIT model and current earnings profile. See our latest analysis for RLJ Lodging Trust. Recent trading has been softer, with a 1 month share price return showing a decline of 6.73% and a year to date share price return showing a decline of 2.22%. The 1 year total shareholder return of 0.71% hints at only modest overall...

Tetra Tech (NasdaqGS:TTEK) has appointed Eric W. Thornburg, a water industry veteran with over 40 years of sector experience, to its Board of Directors. Thornburg most recently served as CEO of H2O America, adding executive leadership experience directly tied to water infrastructure and services. The board appointment reflects a focus on water and utilities oriented governance at a time when water infrastructure and environmental solutions remain central to Tetra Tech's business. Tetra Tech...

On March 19, 2026, Box increased its share repurchase authorization by US$500 million to a total of US$1.86 billion and extended the program through September 30, 2027. Alongside this larger buyback, co-founder Aaron Levie outlined an AI-focused plan that channels automation savings into human-led customer success, underscoring how Box aims to blend technology gains with service expansion. We’ll now examine how Box’s expanded US$1.86 billion buyback program influences its investment...

Booz Allen Hamilton recently announced it was selected by the National Weather Service to build a first-of-its-kind cloud-based data platform, while also advancing its AI-native Vellox cyber defense suite and investing in AI-RAN firm ODC for future 5G and 6G applications. Together, these moves highlight Booz Allen’s growing role in mission-critical federal cloud, cybersecurity, and AI-infused network infrastructure that underpins US national resilience. We’ll now examine how Booz Allen’s new...

In March 2026, Hormel Foods announced it had fully integrated AI-powered demand and supply planning across more than 70 global sites via the o9 Digital Brain platform in collaboration with Accenture, while also affirming a quarterly dividend of US$0.2925 per share and being removed from the FTSE All-World Index (USD). This combination of advanced digital supply chain capabilities and ongoing brand innovation, particularly in premium and globally inspired pizza toppings, underscores Hormel’s...

Crown Holdings (CCK) shares are in focus after the company expanded Dr. John M. Rost’s responsibilities to Executive Vice President and Chief Operating Officer, Asia Pacific and Transit Packaging, a move centered on two key revenue segments. See our latest analysis for Crown Holdings. The executive reshuffle comes after a 1-month share price return decline of 13.11% and a year-to-date share price return decline of 4.42%, while the 1-year total shareholder return stands at 12.81%. This...

In March 2026, Xenon Pharmaceuticals’ chief medical officer Christopher John Kenney reported a routine, tax-related sale of 1,410 vested restricted stock unit shares, worth about US$78,000, executed under a sell-to-cover instruction. This insider transaction followed Xenon’s positive topline Phase 3 results for lead candidate azetukalner and the completion of an upsized offering of nearly US$750 million, underscoring the company’s progress in both clinical development and capital...

Why Seaboard (SEB) is on investors’ radar today Seaboard (SEB) has drawn attention after recent share price moves, including a 2.18% 1 day return and double digit gains over the past week, month and past 3 months. Those swings are prompting investors to look more closely at how Seaboard’s diversified operations in pork, commodity trading, marine shipping, fuels, power and turkey production, together with its current valuation metrics, fit into their broader portfolio decisions. See our latest...

Index inclusion puts Lamb Weston Holdings (LW) on more investor radars Lamb Weston Holdings (LW) was added to the Russell Small Cap Value Index on 20 March 2026, a shift that can draw new attention as index funds and passive vehicles adjust their holdings. This kind of index inclusion often prompts mechanical buying from funds that track the benchmark, which can change trading volumes and ownership patterns even if the company’s operations and fundamentals remain unchanged. See our latest...

Why Nasdaq’s tokenized collateral move with Talos matters Nasdaq (NDAQ) is drawing fresh attention after announcing a partnership with Talos to integrate tokenized collateral workflows into its Calypso and Trade Surveillance platforms. This step directly targets institutional use of digital assets. See our latest analysis for Nasdaq. Despite headlines around tokenized collateral and Nasdaq’s presence at the Digital Asset Summit, the stock’s recent momentum has softened, with a 17.6% 90-day...

NewAmsterdam Pharma announced it would present multiple Phase 3 and outcomes-related data sets for its oral CETP inhibitor obicetrapib at the ACC.26 cardiology meeting in New Orleans, highlighting kidney function, safety and lipid-related cardiovascular risk metrics in high‑risk patients. An interesting angle for investors is that obicetrapib is being positioned as a low‑dose, oral option intended to complement or expand existing LDL‑lowering approaches, with European commercialization...

Assessing OneMain Holdings after recent share price pressure OneMain Holdings (OMF) has come under pressure recently, with the stock showing declines over the past week, month and past 3 months. This has prompted investors to reassess its valuation and recent financial profile. See our latest analysis for OneMain Holdings. The current share price of US$51.55 reflects recent weakness, with a 1 month share price return of a 6.31% decline and a year to date share price return of a 25.37%...

CrowdStrike recently unveiled a wave of AI- and agent-focused upgrades to its Falcon platform, expanded collaborations with IBM and Intel, and new offerings like Agentic MDR, Falcon Data Security, and Charlotte AI AgentWorks, while deepening ecosystem ties with partners including AWS, NVIDIA, EY, Nebius, and WWT. These moves position CrowdStrike at the center of “agentic SOC” and AI security workflows just as investors are increasingly worried that powerful new frontier AI models such as...

In March 2026, Dell Technologies (NYSE:DELL) introduced a reimagined commercial device portfolio aimed at enterprise users. The new Dell Pro notebooks and desktops feature AI ready hardware, Copilot+ experiences, modular design, and updated Intel and AMD chips. The launch shifts attention from Dell's earlier focus on AI servers and quantum security to client devices used by everyday workers and IT teams. Dell Technologies enters this product cycle with recent share price momentum, with...

If you are wondering whether Berkshire Hathaway's current share price offers value or mainly reflects reputation, the key is to look past the ticker and focus on what the underlying valuation signals are actually saying. The stock last closed at US$468.49, with returns of a 2.4% decline over 7 days, a 7.2% decline over 30 days, a 5.7% decline year to date, and a 12.0% decline over the past year, compared with gains of 51.0% over 3 years and 78.4% over 5 years. Recent coverage has focused on...

Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and children 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment, adding to the drug’s existing rare obesity indications. This European regulatory milestone, coming shortly after U.S. approval for acquired hypothalamic obesity, reinforces Rhythm’s focus on...

IHS Holding (NYSE:IHS) has drawn investor attention after recent share price moves, prompting a closer look at how its current valuation, business mix, and return profile line up for long term holders. See our latest analysis for IHS Holding. At a share price of $8.21, IHS Holding’s recent 30 day share price return of 2.62% and 90 day share price return of 9.91% sit alongside a 1 year total shareholder return of 57.28%. However, the 3 year total shareholder return is slightly negative, which...

Johnson & Johnson (NYSE:JNJ) has secured European approval for self or caregiver administration of Darzalex in multiple myeloma. The decision covers all ten approved indications for Darzalex and makes it the first oncology injectable in Europe to receive this type of authorization. The new label allows eligible patients to receive treatment at home instead of exclusively in hospital or clinic settings. For Johnson & Johnson, which has a large pharmaceutical segment focused on oncology and...

Earlier in March 2026, QUALCOMM held its annual shareholder meeting, increased its quarterly dividend to US$0.92 per share, authorized a US$20.00 billion buyback, and filed a US$3.13 billion common share shelf registration tied to an employee stock ownership plan, while shareholder proposals on special meetings and China risk reporting were not approved. These moves highlight QUALCOMM’s focus on capital returns and employee ownership at the same time some investors are pushing for greater...

AbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 abstracts across psoriasis, atopic dermatitis, vitiligo and alopecia areata, including late-stage and long-term safety data. See our latest analysis for AbbVie. Despite the strong dermatology update, recent partnerships, and governance debates, AbbVie’s share price has slipped in recent months. Its year to...

For investors considering whether Artivion at around US$35 per share still offers value or whether the recent run has already priced in the story, this article breaks down what the current market price might be implying. The stock has pulled back over the last week and month, with declines of 1.2% and 8.3%, respectively, while still sitting on a 43.6% return over 1 year and 176.1% over 3 years. Recent coverage has focused on Artivion's position in the medical equipment space and investor...

In March 2026, Colgate-Palmolive disclosed past shareholder proposals seeking an independent board chair and removal of DEI criteria from board candidate selection, while federal lawsuits challenged its mouth rinse packaging over alleged safety messaging for young children. These governance and legal pressures arrive just as Colgate-Palmolive promotes its new Optic White Pro Series Toothpaste, highlighting how product innovation now sits alongside intensified scrutiny of its board structure,...